Nanocarrier compositions with uncoupled adjuvant

a technology of adjuvant and composition, applied in the direction of powder delivery, macromolecular non-active ingredients, inorganic non-active ingredients, etc., can solve the problem of not yet known optimal approach for augmenting the immune response with adjuvan

Inactive Publication Date: 2011-12-01
SELECTA BIOSCI
View PDF4 Cites 84 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]In one embodiment, the synthetic nanocarriers comprise one or more polymers. In another embodiment, the one or more polymers comprise a polyester. In yet another embodiment, the one or more polymers comprise or further comprise a polyester coupled to a hydrophilic polymer. In a further embodiment, the polyester comprises a poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), or polycaprol

Problems solved by technology

The optimal approach for augmenting the immune response wit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanocarrier compositions with uncoupled adjuvant
  • Nanocarrier compositions with uncoupled adjuvant
  • Nanocarrier compositions with uncoupled adjuvant

Examples

Experimental program
Comparison scheme
Effect test

example 1

Administration of Nanocarrier and Admixed R848 Adjuvant Results in Strong Systemic Production of Inflammatory Cytokines

Materials for NC-R848-1 Nanocarrier Formulations

[0146]Ovalbumin peptide 323-339 amide acetate salt, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505. Part #4065609.) PLGA-R848 conjugate of 75 / 25 lactide / glycolide monomer composition and of approximately 4100 Da molecular weight having 5.2% w / w R848 content was synthesized. PLA-PEG-Nicotine with a nicotine-terminated PEG block of approximately 3,500 Da and DL-PLA block of approximately 15,000 Da was synthesized Polyvinyl alcohol (Mw=11,000-31,000, 87-89% hydrolyzed) was purchased from J.T. Baker (Part Number U232-08).

Methods for NC-R848-1 Nanocarrier Production

[0147]Solutions were prepared as follows:

[0148]Solution 1: Ovalbumin peptide 323-339 @ 70 mg / mL was prepared in 0.13N hydrochloric acid at room temperature.

[0149]Solution 2: PLGA-R848 @ 75 mg / mL and PLA-PEG-Nicotine @ 25 mg / mL...

example 2

Coupling of Nanocarrier to R848 Adjuvant does not Inhibit Systemic Production of Immune Cytokine IFN-γ

Materials for NC-R848 Nanocarrier Formulations

[0168]Ovalbumin peptide 323-339 amide acetate salt was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505. Part #4065609.) PLGA-R848 conjugate of 75 / 25 lactide / glycolide monomer composition and of approximately 4100 Da molecular weight having 5.2% w / w R848 content was synthesized. PLA-PEG-Nicotine with a nicotine-terminated PEG block of approximately 3,500 Da and DL-PLA block of approximately 15,000 Da was synthesized. Polyvinyl alcohol (Mw=11,000-31,000, 87-89% hydrolyzed) purchased from J.T. Baker (Part Number U232-08).

Methods for NC-R848 Nanocarrier Production

[0169]Solutions were prepared as follows:

[0170]Solution 1: Ovalbumin peptide 323-339 @ 70 mg / mL was prepared in 0.13N hydrochloric acid at room temperature.

[0171]Solution 2: PLGA-R848 @ 75 mg / mL and PLA-PEG-Nicotine @ 25 mg / mL in dichloromethane was p...

example 3

Addition of Free Adjuvant Augments Immune Response

Materials for NC-Nic w / o R848 Nanocarrier Formulations

[0183]Ovalbumin peptide 323-339 amide TFA salt was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505. Part #4064565.) PLA with an inherent viscosity of 0.19 dL / g was purchased from Boehringer Ingelheim (Ingelheim Germany. Product Code R202H). PLA-PEG-Nicotine with a nicotine-terminated PEG block of approximately 3,500 Da and DL-PLA block of approximately 15,000 Da was synthesized. Polyvinyl alcohol (Mw=11,000-31,000, 87-89% hydrolyzed) was purchased from J.T. Baker (Part Number U232-08).

Methods for NC-Nic w / o R848 Nanocarrier Production

[0184]Solutions were prepared as follows:

[0185]Solution 1: Ovalbumin peptide 323-339 @ 69 mg / mL was prepared in 0.13N hydrochloric acid at room temperature.

[0186]Solution 2: PLA @ 75 mg / mL and PLA-PEG-Nicotine @ 25 mg / mL in dichloromethane was prepared by dissolving PLA @ 100 mg / mL in dichloromethane and PLA-PEG-Nicotin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.

Description

RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119 of U.S. provisional applications 61 / 348,713, filed May 26, 2010, 61 / 348,717, filed May 26, 2010, 61 / 348,728, filed May 26, 2010, and 61 / 358,635, filed Jun. 25, 2010, the entire contents of each of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]This invention relates to synthetic nanocarrier and separate adjuvant compositions, and related methods, such as for treating diseases in which generating an immune response is desirable.BACKGROUND OF THE INVENTION[0003]Adjuvants are generally important components for the majority of currently used vaccination regimens. The optimal approach for augmenting the immune response with adjuvant, however, in a number of cases, is not yet known. Therefore, improved compositions and therapeutic methods are needed to provide improved therapies for diseases in which generating an immune response and / or augmenting it is desirable.SUMMARY OF THE INVEN...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K47/30A61K47/42A61K39/385A61P29/00A61K9/14A61P35/00A61P31/00A61P17/00A61P11/06A61P11/00A61K39/00A61P37/00
CPCA61K9/5153A61K2039/55522A61K31/7115A61K33/06A61K39/0013A61K39/385A61K39/39A61K45/06A61K47/02A61K47/22A61K47/24A61K47/48176A61K47/482A61K47/48215A61K47/48853A61K2039/555A61K2039/55511A61K2039/55555A61K2039/6093A61K31/4745A61K2300/00A61K47/34A61K39/12C12N2730/10134C12N2760/16134A61K2039/6031A61K2039/60A61K2039/55561A61K2039/70A61K2039/6087A61K47/60A61K47/58A61K47/593A61K47/6921A61P1/16A61P11/00A61P11/06A61P11/08A61P17/00A61P17/04A61P25/28A61P25/30A61P25/34A61P25/36A61P29/00A61P3/00A61P31/00A61P31/04A61P31/10A61P31/12A61P31/14A61P31/16A61P31/20A61P31/22A61P35/00A61P37/00A61P37/02A61P37/04A61P37/08A61P39/02A61P43/00A61P5/00Y02A50/30A61K9/16A61K39/00A61K38/00A61K38/17A61K39/395A61K2039/62A61K2039/545A61K39/0005A61K39/35A61K2039/54A61K2039/541A61K2039/542A61K2039/543A61K47/6931A61K47/68A61K47/646A61K47/6929
Inventor BRATZLER, ROBERT L.JOHNSTON, LLOYDLIPFORD, GRAYSON B.ZEPP, CHARLES
Owner SELECTA BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap